

Tunisia COVID-19 Response project (P173945)

MIDDLE EAST AND NORTH AFRICA | Tunisia | Health, Nutrition & Population Global Practice | IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 2 | ARCHIVED on 25-Mar-2021 | ISR45379 |

Implementing Agencies: Republic of Tunisia, Ministry of Health

Key Dates

Key Project Dates

Bank Approval Date: 30-Apr-2020 Effectiveness Date: 01-Jun-2020
Planned Mid Term Review Date: 20-Apr-2022 Actual Mid-Term Review Date:
Original Closing Date: 30-Jun-2021 Revised Closing Date: 30-Jun-2021

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To improve COVID-19 detection and infection control in Tunisia through increasing the availability of COVID-19 equipment and supplies.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Emergency COVID-19 Response:(Cost \$19.85 M)
Implementation Management and Monitoring and Evaluation:(Cost \$0.10 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	□Satisfactory	□Satisfactory
Overall Implementation Progress (IP)	□Satisfactory	Satisfactory
Overall Risk Rating	□Moderate	Moderate

Implementation Status and Key Decisions

The project was approved by the World Bank's Executive Board on April 30, 2020 and was declared effective on June 1st, 2020. The project is financed by a US\$20 million loan under the Multiphase Programmatic Approach supported by the Fast Track COVID-19 Facility. The project will be implemented over 13 months until June 30, 2021. The disbursement rate is 100 percent, with US\$20 million fully disbursed through an advance to purchase goods and services for COVID-19 response in Tunisia.

MPA Program Development Objective

3/25/2021 Page 1 of 5

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

The implementation of the MPA-funded projects continues to progress well. As of March 15, 2021, 86 MPA-projects have been approved providing a total commitment of US\$4.20 billion. Disbursements have continued to increase at a rapid pace. Thirty four (34) country projects or 40% of projects approved have reached 70-100% disbursements. The projects benefit around 3.7 billion people or 50% of the global population. Of the 86 approved projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 13 in Europe and Central Asia; (iv) 12 in Latin America and the Caribbean; (v) 7 in Middle East and North Africa; and (vi) 9 in South Asia. Seventy two (72) projects are disbursing. Total disbursements as of March 15, 2021 under these projects amount to US\$2,139.8 million or 51% of overall commitments. In addition, \$641 million have been committed under signed contracts with UNICEF and Bank Facilitated Procurement. Streamlined procedures, delegated approval coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Several projects have/are being restructured to include vaccine related procurement. Implementation continues to face challenges as some countries are still under different levels of lockdown or mobility restrictions and counterparts and Bank teams are operating from home. Bank teams continue to conduct implementation support missions virtually, which is challenging for both Bank teams and counterparts. This creates connectivity challenges as internet is not reliable in many of the IDA countries. Notwithstanding challenges, the MPA is on track to achieving its PDO – to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements in just over eleven months attest to the strong implementation of the Bank response thanks to the commitment of counterparts supported by country teams.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	□Moderate	Moderate	Moderate
Macroeconomic	Substantial	Substantial	Substantial
Sector Strategies and Policies	□Moderate	□Moderate	□Moderate
Technical Design of Project or Program	□Moderate	□Moderate	□Moderate
Institutional Capacity for Implementation and Sustainability	Substantial	Substantial	Substantial
Fiduciary	Substantial	Substantial	Substantial
Environment and Social	□Moderate	□Moderate	□Moderate
Stakeholders	□Moderate	□Moderate	□Moderate
Other			
Overall	□Moderate	□Moderate	□Moderate

Results

3/25/2021 Page 2 of 5

PDO Indicators by Objectives / Outcomes

To improve COVID-19 detection and infection control by increasing the availability of equipment

▶ Number of health facilities and laboratories provided with personal protective equipment under the project (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	263.00	228.00
Date	30-Apr-2020	16-Jul-2020	03-Feb-2021	30-Jun-2021

▶ Number of tests conducted for COVID-19 using Polymerase Chain Reaction (PCR) machines (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	17,558.00	17,588.00	766,397.00	600,000.00
Date	27-Apr-2020	16-Jul-2020	03-Feb-2021	30-Jun-2021

Intermediate Results Indicators by Components

Emergency COVID-19 response

▶ Percentage of Project supported health facilities and laboratories confirming receipt of equipment within 14 days of in-country delivery of such equipment (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	100.00	100.00
Date	30-Apr-2020	16-Jul-2020	03-Feb-2021	30-Jun-2021

Implementation Management and Monitoring and Evaluation

▶ Percentage of sampled Project supported health facilities and laboratories that have received equipment verified for installation and functionality (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	100.00
Date	30-Apr-2020	16-Jul-2020	16-Jul-2020	30-Jun-2021

Performance-Based Conditions


Data on Financial Performance

3/25/2021 Page 3 of 5

Disbursements (by loan)

P173945	IBRD-91120	Effective	30-Apr-2020	11-M	ay-2020	01-Jun-2020	30-Ju	ın-2021	30-Jun-2021	
Project	Loan/Credit/TF	Status	Approval Date	e Signi	ng Date	Effectiveness [Date Orig.	Closing Date	Rev. Closing [Date
Key Dates	(by loan)									
P173945	IBRD-91120	Effective	USD	20.00	20.00	0.00	20.52	0.00		100%
Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Di	isbursed

Cumulative Disbursements



PBC Disbursement

PBC ID	PBC Type De	escription	Coc	Achievement Status	Disbursed amount in Coc	Disbursement % for PBC

3/25/2021 Page 4 of 5

Restructuring History

There has been no restructuring to date.

Related Project(s)

P175785-Additional Financing for Tunisia COVID-19 Response Project

3/25/2021 Page 5 of 5